PFE Pfizer

XNYS Up Alert

Health Care

· How we analyze

About the company

Pfizer is a major US pharmaceutical company. It develops and sells prescription drugs and vaccines, for example for cancer, infections and cardiovascular disease. Most recently it became known for the coronavirus vaccine developed together with Biontech. Pfizer operates worldwide. As of Oct 11, 2026

Fact sheet (from the annual report) Pharmaceutical manufacturers · New York, USA

According to the company, the group researches, develops, manufactures and markets biopharmaceutical products worldwide, and Biopharma is the only reportable segment. In November 2025 the group acquired Metsera. Research focuses on oncology, internal medicine including cardiovascular, metabolism, weight management and migraine, vaccines, and inflammation and immunology. Its products include Eliquis, the Prevnar vaccine family, the Comirnaty vaccine and Paxlovid for COVID. Prescription drugs go mainly to wholesalers and also directly to retailers, hospitals, government agencies and pharmacies. In the US market, vaccines go mainly to the federal government, wholesalers, physician offices, pharmacies and integrated delivery systems.

Automatically summarized from SEC annual report (10-K, filed Feb 26, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

Price performance at a glance

Last 30 trading days
  • Today +0.0%
  • 7 days −1.0%
  • 30 days +3.9%
  • 1 year +20.3%
Day range (last trading day)
−1.0%Price at 83% of the range+0.2%
52-week range
−20.7%Price at 91% of the range+2.1%
Distance from the all-time high
−51.7%

Our own calculation from the exchange’s daily candles, as of Oct 27, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Pullback in trend · Analysis method

The price of PFE is currently in no zone of this method. The check runs daily after the market close.

Whether a price will soon reach a zone, you see from Watcher. Plans and pricing

How the zone is formed

What is this? In an intact uptrend (price above the 200-day line, 50-day line rising), the price pulls back to the 50-day line after a rise and closes back above it.

Buy zone: around the 50-day line (± 0.5 ATR). Stop: 1.5 ATR below it. Target 1: the last high, Target 2: 2 ATR above it.

The pattern is valid for at most 15 trading days and expires if the price falls below the stop. This is a calculated analysis, not a forecast and not a call to buy. Risk notice and investment advice

Load chart from TradingView

This transfers data (including your IP address) to TradingView, also to the USA. More in the Privacy policy.

Symbol on TradingView: NYSE:PFE

Fundamental analysis

Pfizer · Sector Health Care · amounts in USD

Information only – does not affect our buy zones, not investment advice. Source: SEC filings, As of Feb 26, 2026.

In short

  • Light green: Revenue grew over 5 years (+8.5% per year), at least as fast as the sector median.
  • Light red: Net income (total) shrank over 5 years (−4.2% per year); per share −4.5% per year.
  • Light yellow: Net margin 12.4%, below the sector median (12.9%).
  • Light yellow: Debt higher than usual in the sector.
  • Light green: Profit in each of the last 10 fiscal years.
  • Light red: Dividend higher than earnings.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 52.8B USD · Net income 7.2B USD · Net margin 13.7%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 52.5B USD · Net income 21.3B USD · Net margin 40.6%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 53.6B USD · Net income 11.2B USD · Net margin 20.8%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 51.8B USD · Net income 16.3B USD · Net margin 31.4%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 41.7B USD · Net income 9.6B USD · Net margin 23.1%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 81.3B USD · Net income 22.0B USD · Net margin 27.0%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 100.3B USD · Net income 31.4B USD · Net margin 31.3%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 58.5B USD · Net income 2.1B USD · Net margin 3.6%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 63.6B USD · Net income 8.0B USD · Net margin 12.6%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 62.6B USD · Net income 7.8B USD · Net margin 12.4%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 62.6B USD · Net income 7.8B USD · Net margin 12.4%

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light green: above sector

+8.5% per year, last 5 years

Sector Health Care: median +7.8% (60 symbols)

What does this mean? Revenue: over 5 years it grew by 8.5% per year on average – at least as fast as the median company in the sector (+7.8%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light red: shrinking

−4.2% per year, last 5 years

Sector Health Care: median +7.5% (46 symbols)

per share: −4.5% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it fell by 4.2% per year on average. The median company in the sector reached +7.5% per year.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light yellow: below sector

12.4% last fiscal year

Sector Health Care: median 12.9% (63 symbols)

What does this mean? Of every 100 USD in revenue, 12.42 USD remained as profit – less than the median company in the sector (12.9%). Five years ago the margin was 23.1%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light yellow: higher than sector

0.71 latest balance sheet

Sector Health Care: median 0.66 (40 symbols)

What does this mean? For every 1 USD of equity there is 0.71 USD of financial debt – more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light red: above earnings

126% Dividend / earnings per share

Sector Health Care: median 28% (31 symbols)

What does this mean? The payout was higher than the earnings per share; it is paid from cash flow, from reserves or with new debt. Median company in the sector: 28%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
62.6B USD
Revenue vs. prior year
−1.6%
Net income (FY)
7.8B USD
Net income vs. prior year
−3.2%
EPS (FY)
1.36 USD
13F funds with a position
1 of 9
Funds vs. prior quarter
±0
Shares held vs. prior quarter
−84.0%
Fiscal year to Dec 31, 2025 · 10-K filed Feb 26, 2026 · Balance sheet Jun 28, 2026 (filed Aug 4, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). 13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 62.6B7.8B 12.4% 1.36 1.72 126%
2024Dec 31, 2024 63.6B8.0B 12.6% 1.41 1.69 120%
2023Dec 31, 2023 58.5B2.1B 3.6% 0.37 1.65 446%
2022Dec 31, 2022 100.3B31.4B 31.3% 5.47 1.61 29%
2021Dec 31, 2021 81.3B22.0B 27.0% 3.85 1.57 41%
2020Dec 31, 2020 41.7B9.6B 23.1% 1.71 1.53 89%
2019Dec 31, 2019 51.8B16.3B 31.4% 2.87 1.46 51%
2018Dec 31, 2018 53.6B11.2B 20.8% 1.87 1.38 74%
2017Dec 31, 2017 52.5B21.3B 40.6% 3.52 1.30 37%
2016Dec 31, 2016 52.8B7.2B 13.7% 1.17 1.22 104%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q2/26Jun 28, 2026 15.0B−248.0M −1.6% −0.04 0.86 –
Q1/26Mar 29, 2026 14.5B2.7B 18.6% 0.47 0.00 0%
Q4/25*Dec 31, 2025 17.6B−1.6B −9.4% – 0.86 –
Q3/25Sep 28, 2025 16.7B3.5B 21.3% 0.62 0.00 0%
Q2/25Jun 29, 2025 14.7B2.9B 19.9% 0.51 0.86 169%
Q1/25Mar 30, 2025 13.7B3.0B 21.6% 0.52 0.00 0%
Q4/24*Dec 31, 2024 17.8B410.0M 2.3% – 0.85 –
Q3/24Sep 29, 2024 17.7B4.5B 25.2% 0.78 0.00 0%
Q2/24Jun 30, 2024 13.3B41.0M 0.3% 0.01 0.84 8,400%
Q1/24Mar 31, 2024 14.9B3.1B 20.9% 0.55 0.00 0%
Q4/23*Dec 31, 2023 14.2B−3.4B −23.6% – 0.83 –
Q3/23Oct 1, 2023 13.2B−2.4B −18.0% −0.42 0.00 –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $3.0M3 people $83.3K1 person +$2.9M
6 months $3.0M3 people $134.7K1 person +$2.8M
12 months $3.0M3 people $134.7K1 person +$2.8M

Latest transactions

  • Aug 12, 2026 Bourla Albert Chief executive (CEO), Director Open-market purchase 38,000 shares · $1.0M · SEC
  • Aug 5, 2026 Damico Jennifer B. Officer Open-market sale 3,278 shares · $83.3K · SEC
  • Aug 5, 2026 Blaylock Ronald E Director Open-market purchase 39,231 shares · $998.8K · SEC
  • Aug 5, 2026 Buckley Mortimer J Director Open-market purchase 37,632 shares · $960.4K · SEC
  • Jun 9, 2026 Damico Jennifer B. Officer Open-market sale 2,000 shares · $51.4K · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Trend score +80

Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+15
Highs and lows+0
Relative strength+15

Volatility and trend strength

ADX 14 (trend strength)29.0
Rel. strength 60 d+17.9%

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on PFE yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: PFE

Alerts with a free account: we send you an email as soon as the price moves above or below your level, reaches the buy zone or the buy zone becomes invalid.

Checked after every data update: crypto hourly (buy zones every 4 hours), stocks twice a day, precious metals every 4 hours on trading days, extended universe weekly – not in real time.

Log in Sign up free

↑ ↓ select · Enter open · Esc close